Mark Froimson, Director at Pacira Pharmaceuticals, Inc. (PCRX), bought 100 shares at $37.13 ($4K) on 2017-08-08, disclosed to the SEC on 2017-08-16.
Open-market purchase of $4k PCRX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| PCRX | SELL | 2022-05-11 | $59K | — | Filing → |
| PCRX | SELL | 2021-03-17 | $106K | — | Filing → |